ALVO OAKTREE ACQUISITION CORP II

Viðskipti stjórnenda og tengdra aðila

Viðskipti stjórnenda og tengdra aðila

Í viðhengi er tilkynning um viðskipti stjórnenda og tengdra aðila sem lögð var inn til birtingar hjá fjármálaeftirliti Lúxemborgar, Luxembourg Commission de Surveillance du Secteur Financier (CSSF), um kaup Alvogen Lux Holdings S.ár.l. á 95,000 hlutum í Alvotech á genginu 1.260 íslenskar krónur á hlut. Kaupin fóru fram þann 20. maí sl. Alvogen Lux Holdings er annar stærsti hluthafi Alvotech. Stærstu hluthafar Alvogen Lux Holdings eru fjárfestingasjóðirnir CVC (40%), Aztiq (30%) og Temasek (20%).

Viðhengi



EN
23/05/2025

Underlying

ALVOOAKTREE ACQUISITION CORP II

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OAKTREE ACQUISITION CORP II

 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Transactions of Managers and Closely Associated Persons

Transactions of Managers and Closely Associated Persons Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 95,000 shares in Alvotech at ISK 1,260 per share, by Alvogen Lux Holdings S.ár.l., the second largest shareholder in Alvotech. The date of the transaction is May 20, 2025. Alvogen Lux Holdings' largest shareholders are CVC (40%), Aztiq (30%) and Temasek (20%). Attachment

8h / 59m 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Viðskipti stjórnenda og tengdra aðila

Viðskipti stjórnenda og tengdra aðila Í viðhengi er tilkynning um viðskipti stjórnenda og tengdra aðila sem lögð var inn til birtingar hjá fjármálaeftirliti Lúxemborgar, Luxembourg Commission de Surveillance du Secteur Financier (CSSF), um kaup Alvogen Lux Holdings S.ár.l. á 95,000 hlutum í Alvotech á genginu 1.260 íslenskar krónur á hlut. Kaupin fóru fram þann 20. maí sl. Alvogen Lux Holdings er annar stærsti hluthafi Alvotech. Stærstu hluthafar Alvogen Lux Holdings eru fjárfestingasjóðirnir CVC (40%), Aztiq (30%) og Temasek (20%). Viðhengi ...

8h / 59m 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockho...

Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 19, 2025) — Alvotech (NASDAQ: ALVO, the “Company”) has entered into agreement with DNB Carnegie Investment Bank AB (publ) (“DNB Carnegie”) regarding liquidity provider services to ensure liquidity in the Company’s Swedish Depository Receipts (“SDRs”), equity share equivalents, trading on Nasdaq Stockholm. The arrangement is in accordance with the framework of Nasdaq Stockholm’s rules on liquidity providers. In the role of liquidity provider, DNB Carnegie undertakes to cont...

May 19, 2025 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Alvotech semur við fjárfestingabankann DNB Carnegie um viðskiptavakt á...

Alvotech semur við fjárfestingabankann DNB Carnegie um viðskiptavakt á Nasdaq markaðnum í Stokkhólmi Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hefði gengið frá samningi við DNB Carnegie Investment Bank AB (“DNB Carnegie”) um viðskiptavakt með bréf félagsins á Nasdaq markaðnum í Stokkhólmi. Sænsk heimildarskírteini (SDR), sem eru ígildi hlutabréfa í Alvotech, hafa verið tekin til viðskipta á markaðnum í Stokkhólmi. Samkvæmt samningnum gefur DNB Carnegie daglega út virk kaup og sölutilboð á Nasdaq markaðnum í Stokkhólmi, fyrir heimildarskírteinin í Alvotech, í samræmi við reglur ...

May 19, 2025 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Trading in Alvotech’s Shares on Nasdaq Stockholm Commences Today

Trading in Alvotech’s Shares on Nasdaq Stockholm Commences Today Not to be released, published, distributed or circulated in any jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 19, 2025) — On May 16, 2025 Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced the outcome of the offe...

May 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch